Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Venetoclax in Pediatric Relapsed/Refractory AML
NCT06191978Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inqovi and venetoclax in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Started Mar 2024; status: recruiting.
02
Drugs
inqovivenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06191978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191978.